TEDA BIOMEDICAL Posts Interim Turnaround with Shareholder Profit of RMB 10.21 Million
Stock News
Aug 31
TEDA BIOMEDICAL (08189) has released its interim results for the six months ended June 30, 2026, marking a significant financial rebound.
The group reported a turnover of RMB 296 million, reflecting a substantial increase of 30.75% compared to the same period last year. More notably, the company swung to a profit attributable to shareholders of RMB 10.21 million, a stark contrast to the loss of RMB 6.43 million recorded during the corresponding period in the previous year.
Earnings per share stood at 0.048 cents, underscoring the company's improved financial health and successful turnaround strategy during the reporting period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.